Glycotest

Glycotest is a US-based liver diagnostics company seeking to commercialise new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis with exclusive world-wide rights to over 50 patent-protected serum protein biomarkers.

Glycotest’s lead product is its HCC panel, a biomarker panel driven by a proprietary algorithm for curable early-stage hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The market for HCC testing is large and growing with currently three million patients and in excess of US$800m in the US alone.

... consult our Annual Report for more information ...

Sector

Diagnostics – Liver

Management Team

Larry Cohen, CEO

Company HQ

Philadelphia, PA, US

Website

www.glycotest.com

Video